Science & Technology
Discovery and optimization of novel, selective HDAC11 inhibitors for the treatment of obesity and related diseases.
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1R44DK139886-01
Award Ceiling
$324K
Award Floor
$324K
Close Date
Jun 30, 2025
Total Funding
$324K
Expected Awards
1
Posted Date
Jul 25, 2024
Cost Sharing Required
No
Grants.gov ID
sbir-1R44DK139886-01
Description
SBIR Phase Phase I award: "Discovery and optimization of novel, selective HDAC11 inhibitors for the treatment of obesity and related diseases." awarded to Myracle Therapeutics Inc in EAST HANOVER, New Jersey. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $324,466. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.